WHAT IS CLAIMED IS:

1. A solid pharmaceutical formulation comprising a plurality of microcrystalline cellulose pellets each individually coated with a composition comprising:

6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;

a polymeric stabilizer;

an ionic surfactant; and

a non-ionic surfactant.

2. The formulation of claim 1, wherein:

the polymeric stabilizer includes polyvinylpyrollidone;

the ionic surfactant includes sodium docusate; and

the non-ionic surfactant includes a poloxamer or a PEGylated phospholipid.

3. The formulation of any one of claims 1 to 2, wherein:

the polymeric stabilizer is polyvinylpyrollidone K-30;

the ionic surfactant is sodium docusate; and

the non-ionic surfactant is poloxamer 407.

4. The formulation of any one of claims 1 to 3, wherein the composition further comprises trehalose.

5. The formulation of any one of claims 1 to 4, wherein the composition comprises, on a w/w% basis:

from 20 to 75% of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;

from 1 to 20% of polyvinylpyrollidone K-30;

from 0.01 to 1.00% of sodium docusate; and

from 20 to 60% of poloxamer 407.

6. The formulation of any one of claims 1 to 5, wherein the formulation includes, on a w/w% basis:

from 10 to 50% of microcrystalline cellulose;

from 20 to 50% of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;

from 0.1 to 10% of polyvinylpyrollidone K-30;

from 0.01 to 1.00% of sodium docusate; and

from 10 to 40% of poloxamer 407.

7. The formulation of any one of claims 1 to 6, wherein the formulation further comprises a lubricant.

8. The formulation of claim 7, wherein the lubricant includes sodium stearyl fumarate.

9. The formulation of any one of claims 7 to 8, wherein the formulation includes, on a w/w% basis:

from 25 to 40% of microcrystalline cellulose;

from 25 to 45% of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;

from 3 to 7% of PVP K30;

from 0.05 to 0.50% of sodium docusate;

from 15 to 35% of poloxamer 407; and

from 0.01 to 0.5% of sodium stearyl fumarate.

10. The formulation of any one of claims 1 to 9, wherein the formulation includes, on a w/w% basis:

from 30 to 35% of microcrystalline cellulose;

from 33 to 39% of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;

from 4.2 to 5.2% of PVP K30;

from 0.2 to 0.3% of sodium docusate;
from 22 to 28% of poloxamer 407; and
from 0.15 to 0.25% of sodium stearyl fumarate.

11. A solid pharmaceutical formulation comprising a plurality of microcrystalline cellulose pellets each individually coated with a composition, wherein the composition consists essentially of, on a w/w% basis:
54.44% of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;
7.08% of PVP K30;
0.38% of sodium docusate; and
38.1% of poloxamer 407.

12. A solid pharmaceutical formulation comprising 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine wherein an oral dose of 50 mg 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine to a human subject provides an AUC_{0-48} of 1850 ng·h/mL ± 30%.

13. A solid pharmaceutical formulation comprising 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine wherein an oral dose of 50 mg 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine to a human subject provides a C_{max} of 352 ng/mL ± 30%.

14. A solid pharmaceutical formulation comprising 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine wherein an oral dose of 50 mg 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine to a human subject provides an AUC_{0-48} of 1850 ng·h/mL ± 30% and a C_{max} of 352 ng/mL ± 30%.

15. A solid unit dosage form of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine comprising the formulation according to any one of claims 1 to 14, wherein the unit dosage form includes 1 to 200 mg of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine in a gelatin capsule.

16. A solid unit dosage form of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine comprising the formulation according to any one of claims 1 to 15, wherein the unit dosage form includes 50, 75, or 100 mg of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine in a gelatin capsule.